M/s. Imres Pharmaceutical Import Profile — Netherlands (DGFT 2022–2026)

Name: M/s. Imres Pharmaceutical Import Records from India — 2 Products, $259.9K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

M/s. Imres — Pharmaceutical Importer Profile (2026) | 2 Products, $259.9K Trade | TransData Nexus

M/s. Imres

Pharmaceutical Importer · Netherlands · Advanced Diabetes Medications Focus · $259.9K Total Trade · DGFT Verified

M/s. Imres is a pharmaceutical importer based in Netherlands with a total trade value of $259.9K across 2 products in 2 therapeutic categories. Based on 13 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. M/s. Imres sources from 1 verified Indian supplier, with Medopharm accounting for 100.0% of imports.

M/s. Imres — Import Portfolio & Supplier Network

M/s. Imres import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to M/s. Imres?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Medopharm	$2.8M	151	100.0%

M/s. Imres sources from 1 verified Indian supplier across 109 distinct formulations. The sourcing is highly concentrated — Medopharm accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does M/s. Imres Import?

Formulation	Value	Ships
Sulfadoxine and pyrimethamine tablets	$108.8K	3
Amoxicillin oral suspension BP 250MG/5ML	$101.1K	4
Azithromycin tablets USP 250MG (153000	$100.0K	2
Albendazole tablets USP 400MG (2700 x	$100.0K	2
Carbamazepine tablets BP 200MG (17000	$71.4K	2
Metformin tablets BP 500MG (6000 x 1000)	$67.8K	2
Zinc sulfate tablets USP 20MG (40000 x	$64.0K	2
Cotrimoxazole tablets BP 480MG (3500 x	$61.6K	2
Erythromycin stearate tablets BP 500MG	$58.6K	2
Hydrochlorothiazide tablets BP 25MG	$57.6K	2
Enalapril maleate tablets USP 5MG	$54.4K	2
Metformin tablets BP 500MG (100100 x	$50.0K	1
Metformin tablets BP 500MG (70745 x 10	$50.0K	1
Azithromycin tablets USP 500MG (134000	$50.0K	1
Paracetamol tablets BP 500MG (15000 x	$50.0K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Glibenclamide	Advanced Diabetes Medications	$142.4K	10	0.3%	4
2	Sulfadoxine	Antimalarial & Antiparasitic	$117.6K	3	0.2%	16

M/s. Imres imports 2 pharmaceutical products across 2 categories into Netherlands totaling $259.9K.

M/s. Imres — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

M/s. Imres B.V., headquartered in Lelystad, Netherlands, is a specialized medical wholesaler with over 35 years of experience in international medical relief and pharmaceutical distribution. Established in 1980, the company focuses on providing high-quality medical solutions to non-governmental organizations (NGOs), governmental bodies, and private entities, particularly in developing countries. Imres offers a comprehensive range of products, including pharmaceuticals, medical kits, equipment, and disposables, catering to the unique needs of its diverse clientele.

In October 2014, Imres became part of Imperial Holdings, a global logistics and supply chain company, which acquired a 70% stake in Imres for €46 million. This strategic acquisition aimed to enhance Imperial's presence in the African pharmaceutical and medical supplies market, leveraging Imres's established network and expertise in the region.

2Distribution Network

Imres operates a state-of-the-art, 6,500-square-meter climate-controlled warehouse in Lelystad, Netherlands, certified for Good Distribution Practice (GDP) and Good Storage Practice (GSP). This facility ensures optimal storage conditions for a wide array of medical products. The company's logistics capabilities include direct shipment, distribution, emergency shipment, and packing services, enabling efficient and timely delivery to various destinations. Imres's geographic coverage extends beyond the Netherlands, with offices in Dubai, India, Canada, China, and the Democratic Republic of Congo, facilitating a global reach in medical supply distribution.

3Industry Role

In the Netherlands's pharmaceutical supply chain, Imres functions primarily as a wholesaler and distributor, specializing in the import and distribution of finished pharmaceutical formulations. The company's focus on supplying medical products to NGOs, governmental bodies, and private organizations positions it as a key player in the international medical relief sector. Imres's role is critical in ensuring the availability of essential medical supplies in regions with developing healthcare infrastructures.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — M/s. Imres

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Imres's sourcing strategy exhibits a high degree of concentration, with a total import value of $260,000 USD from India across 13 shipments, primarily consisting of two products: Glibenclamide and Sulfadoxine. This indicates a strategic choice to focus on specific therapeutic areas, aligning with the company's mission to provide targeted medical solutions. The consistent import pattern suggests a stable and reliable relationship with its sole Indian supplier, MEDOPHARM, which has been the exclusive source for these products. While this single-source dependency may pose risks related to supply chain disruptions, the long-standing partnership and specialized nature of the products mitigate potential concerns.

2Supply Chain Resilience

Imres's supply chain resilience is bolstered by its exclusive partnership with MEDOPHARM, a supplier with a proven track record in delivering quality pharmaceutical products. The company's focus on finished pharmaceutical formulations, rather than raw active pharmaceutical ingredients (APIs), allows for greater control over product quality and compliance with regulatory standards. However, the reliance on a single supplier for specific products may expose Imres to risks associated with supply chain disruptions. To enhance resilience, it would be prudent for Imres to diversify its supplier base and establish contingency plans to mitigate potential disruptions.

Importing Pharmaceuticals into Netherlands — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Netherlands

1Regulatory Authority & Framework

In the Netherlands, the Medicines Evaluation Board (MEB) is the primary regulatory authority responsible for the evaluation and supervision of medicinal products. The MEB ensures that all pharmaceutical products meet the required safety, efficacy, and quality standards before they are authorized for sale. Key legislation governing pharmaceutical imports includes the Medicines Act (Geneesmiddelenwet), which outlines the requirements for marketing authorization, importation, and distribution of medicinal products. For Indian generics to enter the Dutch market, they must obtain a marketing authorization from the MEB, demonstrating compliance with the established criteria. (english.cbg-meb.nl)

2Import Licensing & GMP

Importers of medicinal products into the Netherlands must obtain a pharmaceutical permit from the Dutch Ministry of Health, Welfare, and Sport (VWS). This permit is essential for the legal importation and distribution of pharmaceutical goods. Additionally, Good Manufacturing Practice (GMP) certification is mandatory for manufacturers and importers to ensure product quality and safety. The Netherlands recognizes GMP certifications from the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian exporters seeking to supply Imres and the broader Dutch market must ensure their manufacturing facilities hold valid GMP certifications from these recognized bodies. (business.gov.nl)

M/s. Imres — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Imres's focus on importing Glibenclamide and Sulfadoxine aligns with its strategic objective to provide essential medications for managing diabetes and treating malaria, respectively. The demand for these products is driven by the prevalence of these conditions in developing countries, where Imres primarily operates. By concentrating on these therapeutic areas, Imres can leverage its expertise and established supply chains to meet critical healthcare needs effectively.

2Sourcing Profile

Imres's sourcing strategy emphasizes the importation of finished pharmaceutical formulations, ensuring that products are ready for distribution without the need for further processing. This approach simplifies the supply chain and reduces the time to market. India's robust pharmaceutical manufacturing sector, with its adherence to international quality standards, makes it a suitable partner for Imres's sourcing needs. Indian exporters must ensure that their products meet the specific requirements of Imres and the Dutch regulatory framework to establish a successful partnership.

3Market Positioning

Imres serves a niche segment of the Netherlands's pharmaceutical market, focusing on the import and distribution of essential medications for chronic conditions and infectious diseases. By specializing in these areas, Imres positions itself as a critical supplier to NGOs, governmental bodies, and private organizations involved in healthcare delivery in developing regions. This strategic positioning allows Imres to address specific healthcare challenges effectively and maintain a competitive edge in its target markets.

Seller's Guide — How to Become a Supplier to M/s. Imres

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with Imres, particularly if they can offer high-quality, GMP-compliant finished pharmaceutical formulations in the therapeutic areas of diabetes and malaria. Gaps in Imres's current sourcing may include a limited range of products within these categories or the need for alternative suppliers to mitigate supply chain risks. Indian exporters can capitalize on these opportunities by ensuring product quality, regulatory compliance, and the ability to meet Imres's logistical requirements.

2Requirements & Qualifications

Indian exporters aiming to supply Imres and the Netherlands market must obtain GMP certifications from recognized bodies such as the EU GMP, WHO GMP, or PIC/S. Additionally, they must comply with the Medicines Act (Geneesmiddelenwet) and obtain the necessary marketing authorizations from the Medicines Evaluation Board (MEB) in the Netherlands. Products must meet batch testing, stability, labeling, and serialization requirements to ensure quality and safety. Adhering to these standards is essential for successful market entry and distribution in the Netherlands.

3How to Approach

Frequently Asked Questions — M/s. Imres

What products does M/s. Imres import from India?

M/s. Imres imports 2 pharmaceutical products across 2 categories. Top imports: Glibenclamide ($142.4K), Sulfadoxine ($117.6K).

Who supplies pharmaceuticals to M/s. Imres from India?

M/s. Imres sources from 1 verified Indian suppliers. The primary supplier is Medopharm (100.0% of imports, $2.8M).

What is M/s. Imres's total pharmaceutical import value?

M/s. Imres's total pharmaceutical import value from India is $259.9K, based on 13 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does M/s. Imres focus on?

M/s. Imres imports across 2 categories. The largest: Advanced Diabetes Medications (54.8%), Antimalarial & Antiparasitic (45.2%).

Get Full M/s. Imres Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.